Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 158

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going

Open access
Liang, Chen, Shi, Si, Meng, Qingcai, Liang, Dingkong, Ji, Shunrong, Zhang, Bo, Qin, Yi, Xu, Jin, Ni, Quanxing, Yu, Xianjun · 2017 · Experimental & Molecular Medicine

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating human malignancies. The poor clinical outcome in PDAC is partly attributed to a growth-permissive tumor microenvironment. In the PDAC microenvironment, the stroma is characterized by the development of extensive fibrosis, with stromal components outnumbering pancreatic cancer cells. Each of the components within the stroma has a distinct role in conferring chemoresistance to PDAC, and intrinsic chemoresistance has further worsened this pessimistic prognosis. The nucleoside analog gemcitabine (GEM) is usually the recommended first-line chemotherapeutic agent for PDAC patients and is given alone or in combination with other agents. The mechanisms of intrinsic resistance to GEM are an active area of ongoing research. This review highlights the important role the complex structure of stroma in PDAC plays in the intrinsic resistance to GEM and discusses whether antistroma therapy improves the efficacy of GEM. The addition of antistroma therapy combined with GEM is expected to be a novel therapeutic strategy with significant survival benefits for PDAC patients. The complex environment surrounding pancreatic tumors helps these deadly malignancies to fend off chemotherapy. A drug called gemcitabine is commonly used for pancreatic ductal adenocarcinoma (PDAC), but most tumors become resistant, and patients have only an 8% chance of surviving five years after diagnosis. Xianjun Yu at China's Fudan University in Shanghai and colleagues review how the stroma, the dense mesh of proteins and connective tissue surrounding PDAC tumors, helps promote resistance. They show that the various components of the stroma prevent malignant cells from processing gemcitabine into its active, toxic form, but also help cells to survive the lethal effects of the fully processed drug. Compounds that break down the stromal layer could improve treatment outcome, but researchers first require a deeper understanding of its contents and how they sustain cancerous growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2017.255

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 158

Metadata

Authors
Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X.
Venue
Experimental & Molecular Medicine
Published
2017-12
Volume
49
Issue
12
Pages
e406-e406
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W2774523256
Cited by
158
References
20
FWCI
5.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.